Does a prescription refill count as prescription drug management for E/M?
A refill counts when the note shows a decision: how the condition is doing, the choice to keep or change the medicine, and the follow-up. "Refill metformin" on its own is an order.
By Alex, Chief Medical Officer
A refill counts as prescription drug management when the note shows the clinician checked how the condition is doing and decided to keep, change, start or stop the medicine. A refill order on its own, or a medication list, doesn't show that.
The difference matters because prescription drug management is the AMA's example of moderate risk. Risk is one of the three parts of medical decision making (MDM), the method that sets most office visit levels. The AMA says simply reviewing a medication list doesn't count. Its E/M education describes what does: the clinician records the condition's status, chooses to continue a named medicine, and ties the refill to a follow-up plan.
What does a refill look like with and without a decision?
Here are three plan lines a biller might find on a diabetes follow-up. The patient is 61 and her A1c goal is under 8%.
| Plan line | What a reader can see | Prescription drug management? |
|---|---|---|
| "Refill metformin." | An order. Nothing about how her diabetes is doing or why the medicine continues. | Not shown |
| "Type 2 diabetes. A1c 7.4%, at her goal of under 8%. Continue metformin 1000 mg twice daily. Recheck A1c in 3 months." | Her status against her goal, a decision to continue a named drug and dose, and follow-up | Yes |
| "Type 2 diabetes. A1c 8.6%, up from 7.4% in the spring and above her goal. Increase metformin from 500 mg to 1000 mg twice daily. Recheck A1c in 3 months." | A worsening trend, a dose change and follow-up | Yes |
The first visit may have been just as careful as the other two. The note doesn't show it, and a biller can only level what's written. The second and third lines take one sentence each and name the same four things: the condition, its status against the patient's goal, the decision with the drug and dose, and when it gets checked again.
A decision to continue counts. It's easy to assume only a dose change is "management," but the AMA's own example is a clinician continuing a medicine after checking the condition.
Does prescription drug management make the visit a 99214?
Not by itself. MDM has three parts: the problems addressed, the data reviewed and the risk of the treatment chosen. The visit level is set by two of the three. A moderate risk element moves the level only when one of the other two parts reaches moderate as well.
Here's how the two documented plan lines play out if no new test data counts at this visit, plus a third version where blood pressure is managed too:
| Visit | Problems addressed | Risk | MDM | Level |
|---|---|---|---|---|
| Diabetes at goal, metformin continued | Low: one stable chronic illness | Moderate: prescription drug management | Low | 99213 |
| Diabetes above goal, metformin increased | Moderate: one chronic illness, poorly controlled | Moderate | Moderate | 99214 |
| Diabetes at goal and blood pressure at goal, both medicines continued | Moderate: two stable chronic illnesses | Moderate | Moderate | 99214 |
Two words in that table carry a lot of weight. The AMA defines "stable" by the patient's own treatment goal. A patient who isn't at goal isn't stable, even if nothing changed since last time, so the second visit's diabetes counts as poorly controlled. And a problem counts only when it's addressed today. Blood pressure sitting on the problem list adds nothing; a line that gives today's reading, says it's at goal and continues lisinopril does.
The AMA's E/M FAQ also says there's no blanket rule that a particular medicine or checkbox always sets a risk level. The patient's circumstances and the treatment chosen decide it. So a biller shouldn't raise a level from a refill alone, and shouldn't drop a careful visit because the only change was "continue."
Where do refill visits usually go wrong?
Three patterns show up again and again.
- The plan section is a copied medication list. Every medicine is there, and none has a status or a decision next to it. Nothing in it reads as management.
- The note manages two chronic problems in the exam and plan, but the assessment names only one. The second problem disappears from the level.
- The level is set from the refill box. "Medication management" is checked, the visit is billed as a 99214, and the note shows one stable condition. The level the note supports is 99213.
Each of those can be fixed in a sentence before the note is signed. The chronic condition documentation checklist covers how to write each condition's current status, and how test results count toward MDM covers the data part. For the full comparison of the two most common levels, see 99213 vs 99214.
Cortex Lens reads each note in Practice Fusion before it's signed and shows the visit level its medical decision making supports, 99212 to 99215, up or down, along with what would support the next level. A person makes every change in the chart. Book a demo to see it on your own notes.
Sources: AMA, E/M Updates: How Organizations Are Moving Forward, page 4, on a medication list versus a documented treatment decision. AMA, E/M 2023: Advancing Landmark Updates, FAQ on prescription drug management, page 3, on risk calls needing patient-specific judgment. Both checked October 26, 2026. AMA, 2023 CPT E/M Descriptors and Guidelines, pages 8 to 10, 14 and 15, for the MDM table, "problem addressed" and "stable, chronic illness," checked November 5, 2026.